Octapharma

Symposium

Addressing risks and limitations in haemophilia A: Growing experience
with human cell line-derived rFVIII

 

This scientific symposium will review the risks and life-long limitations currently experienced by the haemophilia A patient population, primarily describing the grave problem of inhibitor development and subsequent bleeding morbidity and mortality. Individual talks will then focus on the use of a human cell-line recombinant FVIII during periods of intensive treatment by continuous infusion, e.g. during major surgery, before looking at the importance of PK-guided personalised prophylaxis to tailor treatment to individual patient needs and potentially reduce the number of infusions whilst maintaining low bleeding rates. An update on clinical study data demonstrating fully Personalised Prophylaxis in previously treated patients (PTPs) will be presented, along with selected case reports.

Wednesday, February 1, 2017

16:00 - 17:30

Location: Paris Marriott Rive Gauche Hotel
& Conference Center, Room AB

Add to Calendar 01/02/2017 16:00 01/02/2017 17:30 Europe/Paris EAHAD Octapharma symposium Addressing risks and limitations in haemophilia A: Growing experience with human cell-line derived rFVIII Location: Paris Marriott Rive Gauche Hotel & Conference Center, Room AB Paris Marriott Rive Gauche Hotel & Conference Center, Room AB DD/MM/YYYY

Ellis Neufeld, USA

Chairman

Welcome and introduction

Current risks and limitations of living with severe haemophilia A

 

Johannes Oldenburg, Germany

Co-chair

FVIII inhibitors and bleeding: A life-long threat

Pål Andrè Holme, Norway

Major surgical procedures with Human-cl rhFVIII: Experience
with intensive treatment at Oslo University Hospital

John Pasi, United Kingdom

Personalised prophylaxis in haemophilia A: The NuPreviq approach

Robert Klamroth, Germany

Case reports in personalised prophylaxis - because no two patients are the same

For EAHAD 2017 Congress participants only

Copyright © 2016 Octapharma - Legal Statement - Privacy Statement - Contact

Octapharma AG, Seidenstrasse 2, CH-8853 Lachen, Switzerland